Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data PLIANT THERAPEUTICS, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
57.1
41.8
7.57
9.69
1.58
0
0
Research and development
47.4
66.2
77.5
96.9
128
169
109
General and administrative
10.9
17.3
27.6
39.9
57.9
59.1
47.2
Operating expenses
58.3
83.5
105
137
186
228
156
Operating income
-1.23
-41.6
-97.5
-127
-184
-228
-156
Interest expense
0
0.79
1.27
3.02
2.56
Interest income
0.82
0.48
Other non-operating income
-0.22
-0.37
Pre-tax income
0.6
41.5
-97.3
-123
-161
-210
-149
Income tax
0
0
0
0
0
0
0
Net income
-0.63
-41.5
-97.3
-123
-161
-210
-149
EBITDA
-0.12
-40.3
-96
-125
-182
-226
-155
EPS, basic
-4.22
-1.95
-2.71
-2.94
-2.75
-3.47
-2.43
EPS, diluted
-4.22
-1.95
-2.71
-2.94
-2.75
-3.47
-2.43
Shares, basic (weighted)
1.62
21.3
35.8
42
58.7
60.5
61.4
Shares, diluted (weighted)
1.62
21.3
35.8
42
58.7
60.5
61.4
Dividend per share
0.00
0.00
0.00
0.00
0.00
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
85.8
50.9
51.7
33.7
63.2
71.2
45.4
Short-term investments
17
226
149
298
431
285
145
Receivables
7.05
9.28
2
1.98
0
Other current assets
1.74
4.5
6.76
7.06
11.3
6.54
4.46
Total current assets
112
291
209
340
506
362
196
Property, plant and equipment
4.08
4.32
4.61
4.49
3.57
5.53
2.94
Lease right-of-use assets
0
6.33
5.42
1.21
27.2
24
Other non-current assets
3.09
0.45
0.84
0.39
0.39
0.44
0.39
Total assets
119
296
221
351
512
397
225
Accounts payable
1.25
2.02
2.97
1.58
4.53
5.96
0.48
Accrued liabilities
6.92
9.58
12
8.66
10.2
12.4
9.63
Total current liabilities
8.17
11.6
16.8
23.9
28.5
33.2
16.4
Lease liabilities
0
5.33
3.43
0
29.4
27.7
Other non-current liabilities
0.91
0.87
0
Total liabilities
9.08
12.5
22.2
37.3
38.6
92.9
44
Total debt
0
9.93
10.1
30.2
0
Paid-in capital
0
401
414
654
973
1,014
1,041
Retained earnings
-76.3
-118
-215
-338
-500
-710
-859
Other comprehensive income
-0
-0.03
-0.2
-1.96
0.35
0.32
-0.02
Shareholders' equity
-76.3
283
199
313
474
304
181
Total equity
-76.3
283
199
313
474
304
181
Total liabilities and equity
119
296
221
351
512
397
225
Shares outstanding
1.85
35.6
36.1
48.9
59.9
60.9
61.4
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-0.63
-41.5
-97.3
-123
-161
-210
-149
Depreciation and amortization
1.11
1.31
1.54
1.82
1.84
2.13
1.7
Stock-based compensation
1.83
3.9
10.4
22.6
44.5
37.6
26.2
Change in receivables
-7.05
-2.23
7.28
0.02
1.98
0
Change in payables
-1.26
0.92
0.89
-1.35
2.97
1.43
-5.48
Cash from operations
-2.75
-37.3
-75.4
-94.6
-116
-156
-128
Capital expenditures
-0.96
-1.53
-1.95
-1.76
-0.92
-3.85
-0.37
Purchases of investments
-51.7
-323
-220
-326
-583
-211
-203
Cash from investing
-17.9
-211
73.7
-150
-127
140
134
Debt issued
0
9.85
0
19.9
0
Debt repaid
0
-32.3
Stock issued
0.17
0.44
2.98
Cash from financing
45.5
213
2.53
227
274
23.1
-31.7
Net change in cash
24.9
-34.9
0.78
-18
31
7.95
-25.7
Free cash flow
-3.71
-38.8
-77.4
-96.4
-117
-159
-129
Interest paid
0
0.62
1.15
2.62
2.54
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.08 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-62.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-48.6%
Net income / average total assets.
Return on invested capital (ROIC)
-63.1%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Book value growth, 1y
-40.4%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-16.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-8.5%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-43.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-13.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-5.3%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
1.4%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
13.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
23.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
9.90x
Current assets / current liabilities.
Quick ratio
9.59x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
9.59x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.00x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
0.0%
Total debt / total assets.
Liabilities / assets
22.6%
Total liabilities / total assets.
Net debt
-$158.1M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$1.14
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.14
Cash from operations / diluted weighted shares.
Book value per share
$2.37
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
0.46x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.46x
Market cap / tangible book value, when positive.
FCF yield
-106.0%
Free cash flow / market cap.
Earnings yield
-138.0%
Net income / market cap (the inverse of P/E).
What was PLIANT THERAPEUTICS, INC.'s revenue in fiscal 2025?
PLIANT THERAPEUTICS, INC. reported revenue of $0.0 for fiscal 2025.
Was PLIANT THERAPEUTICS, INC. profitable in fiscal 2025?
No. It reported a net loss of $149.3M.
How much free cash flow did PLIANT THERAPEUTICS, INC. generate in fiscal 2025?
Cash from operations of $128.3M minus capital expenditures of $374.0K left free cash flow of -$128.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.